Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 9, 2012, Pages 920-928

  Brouwer, Emily S ^a,b   West, Suzanne L ^a,b   Kluckman, Marianne ^a   Wallace, Dennis ^a   Masica, Andrew L ^c   Ewen, Edward ^d   Kudyakov, Rustam ^c   Cheng, Dunlei ^c   Bowen, James ^d   Fleming, Neil S ^c  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BAYLOR HEALTH CARE SYSTEM   (United States)

^d CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

Electronic Health Records; Oral hypoglycemics; Pharmacoepidemiology; Type 2 Diabetes Mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DEXTRO PHENYLALANINE; HEMOGLOBIN A1C; INCRETIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RACE DIFFERENCE;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 84865865373     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2262     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. mber (in Millions) of Civilian/Noninstitutionalized Persons with Diagnosed Diabetes, United States, 1980-2007. 2009; http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed April 26, 2010, 2010.
2. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care Jun 2003; 26(6): 1852-1855.
3. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med Oct 27 2008; 168(19): 2088-2094.
4. Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med Mar 2010; 123(3 Suppl): S12-S18.
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia Jan 2009; 52(1): 17-30.
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care Jan 2009; 32(1): 193-203.
7. Cook MN, Girman CJ, Stein PP, et al. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med Apr 2007; 24(4): 350-358.
8. Filion KB, Joseph L, Boivin JF, et al. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf Oct 2009; 18(10): 973-976.
9. Wandell PE, Brorsson B, Aberg H. Drug prescription in diabetic patients in Stockholm in 1992 and 1995--change over time. Eur J Clin Pharmacol 1997; 52(4): 249-254.
10. Huizinga MM, Roumie CL, Greevy RA, et al. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. Pharmacoepidemiol Drug Saf Nov 2010; 19(11): 1108-1112.
11. Huizinga MM, Roumie CL, Elasy TA, et al. Changing incident diabetes regimens: a Veterans Administration cohort study from 2000 to 2005. Diabetes Care Aug 2007; 30(8): e85.
12. Roumie CL, Huizinga MM, Liu X, et al. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. Pharmacoepidemiol Drug Saf Jan 2011; 20(1): 36-44.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. Sep 12 1998; 352(9131): 837-853.
15. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med Jun 12 2008; 358(24): 2560-2572.
16. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med Jun 12 2008; 358(24): 2545-2559.
17. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med Jan 8 2009; 360(2): 129-139.
18. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med Jun 14 2007; 356(24): 2457-2471.
19. Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009; 339: b2942.
20. Winkelmayer WC, Bucsics AE, Schautzer A, et al. Use of recommended medications after myocardial infarction in Austria. Eur J Epidemiol 2008; 23(2): 153-162.
21. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med Oct 27 2008; 168(19): 2070-2080.
22. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet Jun 20 2009; 373(9681): 2125-2135.
23. Nathan DM. Navigating the choices for diabetes prevention. N Engl J Med Apr 22 2010; 362(16): 1533-1535.
24. Sheehan MT. Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res Jul 2003; 1(3): 189-200.
25. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care Aug 2006; 29(8): 1963-1972.
26. Adams AS, Trinacty CM, Zhang F, et al. Medication adherence and racial differences in A1C control. Diabetes Care May 2008; 31(5): 916-921.
27. Allsworth JE, Toppa R, Palin NC, et al. Racial and ethnic disparities in the pharmacologic management of diabetes mellitus among long-term care facility residents. Ethnicity & disease. Spring 2005; 15(2): 205-212.
28. Shenolikar RA, Balkrishnan R, Camacho FT, et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther Aug 2006; 28(8): 1199-1207.
29. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281(21): 2005-2012.
30. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care Feb 2002; 25(2):330-336.
31. Eurich DT, Simpson SH, Majumdar SR, et al. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy Jun 2005; 25(6): 810-816.
32. Nichols GA, Alexander CM, Girman CJ, et al. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care Mar 2006; 29(3): 504-509.
33. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in medicare managed care. JAMA Mar 13 2002; 287(10): 1288-1294.
34. Gary TL, McGuire M, McCauley J, et al. Racial comparisons of health care and glycemic control for African American and white diabetic adults in an urban managed care organization. Dis Manag. Spring 2004; 7(1): 25-34.
35. Brown AF, Gregg EW, Stevens MR, et al. Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care Dec 2005; 28(12): 2864-2870.
36. Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care Feb 2008; 31(2): 240-246.
37. Duru OK, Gerzoff RB, Selby JV, et al. Identifying risk factors for racial disparities in diabetes outcomes: the translating research into action for diabetes study. Med Care Jun 2009; 47(6): 700-706.
38. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care May 2005; 28(5): 995-1000.